China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 44/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) Resumen de Asistencia Médica y Tuberías
China Traditional Chinese Medicine Holdings Co. Limited, established in 1573, focuses on researching, developing, producing, and selling traditional Chinese medicine and pharmaceutical products. Operating primarily in the People's Republic of China, the company offers a diverse portfolio of TCM products, including granules, finished drugs, and decoction pieces, catering to hospitals and retail pharmacies.
Tesis de Inversión
China Traditional Chinese Medicine Holdings Co. Limited presents a mixed investment profile. The company's long history and established presence in the Chinese TCM market provide a solid foundation. However, the company's negative profit margin of -1.7% and negative ROE of -1.4% raise concerns about profitability and efficiency. With a market capitalization of $1.38 billion and a debt-to-equity ratio of 15.38, the company appears financially stable, but the lack of free cash flow ($0.00B) is a concern. Growth catalysts include expanding its product line and increasing its market share within China. The beta of 0.74 suggests lower volatility compared to the broader market.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $1.38 billion, indicating a significant presence in the TCM market.
- Gross margin of 47.7%, reflecting a strong ability to manage production costs.
- Debt-to-equity ratio of 15.38, suggesting a conservative approach to financial leverage.
- Beta of 0.74, indicating lower volatility compared to the overall market.
- Founded in 1573, demonstrating a long-standing history and established brand in the TCM industry.
Competidores y Pares
Fortalezas
- Long-standing history and established brand in the TCM market.
- Integrated operations, from herb cultivation to product distribution.
- Diverse product portfolio catering to various healthcare needs.
- Established distribution network across China.
Debilidades
- Negative profit margin and return on equity.
- Lack of free cash flow.
- Reliance on the Chinese market.
- Potential quality control issues in TCM production.
Catalizadores
- Ongoing: Expansion of product lines to include innovative TCM formulations.
- Ongoing: Geographic expansion within China to underserved regions.
- Ongoing: Increased investment in R&D to develop evidence-based TCM products.
- Ongoing: Strategic partnerships and acquisitions to expand capabilities.
- Ongoing: Leveraging e-commerce platforms to reach a wider customer base.
Riesgos
- Potential: Stringent regulations and quality control requirements in the pharmaceutical industry.
- Potential: Competition from both domestic and international pharmaceutical companies.
- Potential: Fluctuations in the prices of raw materials.
- Potential: Adverse events related to TCM products.
- Ongoing: Negative profit margin and return on equity.
Oportunidades de crecimiento
- Expansion of TCM Product Lines: China Traditional Chinese Medicine Holdings Co. Limited can capitalize on the growing demand for TCM by expanding its product lines to include innovative formulations and specialized treatments. The global herbal medicine market is projected to reach $129.3 billion by 2028, presenting a significant opportunity for growth. This expansion can be achieved through internal research and development or strategic acquisitions of smaller TCM companies.
- Geographic Expansion within China: The company can further penetrate the Chinese market by expanding its distribution network to reach underserved regions and populations. The Chinese pharmaceutical market is the second-largest in the world, with significant growth potential in rural areas. This expansion can be facilitated through partnerships with local distributors and the establishment of new retail outlets.
- Increased Investment in R&D: Investing in research and development to create new TCM products and improve existing formulations can drive future growth. The company can focus on developing evidence-based TCM products that meet international quality standards. This will not only enhance the company's competitiveness but also open up opportunities for export to international markets.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with other pharmaceutical companies, research institutions, and healthcare providers can accelerate growth and expand the company's capabilities. Acquisitions of complementary businesses can provide access to new technologies, markets, and product lines. These partnerships can also facilitate the development of new TCM products and the improvement of existing formulations.
- Leveraging E-commerce Platforms: The company can leverage e-commerce platforms to reach a wider customer base and increase sales. Online sales of TCM products are growing rapidly in China, driven by the increasing popularity of online shopping. By establishing a strong online presence, the company can tap into this growing market and increase its revenue.
Oportunidades
- Expanding product lines to include innovative TCM formulations.
- Geographic expansion within China to underserved regions.
- Increased investment in R&D to develop evidence-based TCM products.
- Strategic partnerships and acquisitions to expand capabilities.
Amenazas
- Stringent regulations and quality control requirements in the pharmaceutical industry.
- Competition from both domestic and international pharmaceutical companies.
- Fluctuations in the prices of raw materials.
- Potential for adverse events related to TCM products.
Ventajas competitivas
- Established Brand: The company has a long-standing history and a well-recognized brand in the Chinese TCM market, dating back to 1573.
- Integrated Operations: The company's integrated operations, including cultivation of medicinal herbs, manufacturing, and distribution, provide a competitive advantage.
- Extensive Product Portfolio: The company offers a diverse portfolio of TCM products, catering to a wide range of healthcare needs.
- Distribution Network: The company has an established distribution network, reaching hospitals and retail pharmacies across China.
Acerca de CHIZF
China Traditional Chinese Medicine Holdings Co. Limited, tracing its origins back to 1573, is an investment holding company deeply rooted in the research, development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products. Headquartered in Wan Chai, Hong Kong, the company operates primarily within the People's Republic of China. Its comprehensive product portfolio includes granules, finished drugs, decoction pieces, and healthcare products, catering to a broad spectrum of healthcare needs. Beyond its core manufacturing activities, China Traditional Chinese Medicine Holdings Co. Limited is involved in the cultivation and management of Chinese medicinal herbs, ensuring a consistent supply of high-quality raw materials. The company also engages in the trading of pharmaceutical products, provision of TCM marketing, advertising, and consulting services, and retail of pharmaceuticals and decoction products. These diverse activities enable the company to serve hospitals and retail pharmacies effectively. Formerly known as China Traditional Chinese Medicine Co. Limited, the company adopted its current name in July 2016, reflecting its evolution and expanded scope of operations. The company also provides property leasing services.
Qué hacen
- Researches and develops traditional Chinese medicine (TCM) products.
- Produces a range of TCM products, including granules, finished drugs, and decoction pieces.
- Sells its TCM products to hospitals and retail pharmacies.
- Cultivates and manages Chinese medicinal herbs.
- Trades pharmaceutical products.
- Provides TCM marketing, advertising, and consulting services.
- Engages in the retail of pharmaceuticals and decoction products.
- Provides property leasing services.
Modelo de Negocio
- Develops and manufactures TCM products.
- Generates revenue through the sale of TCM products to hospitals and retail pharmacies.
- Supplements revenue through trading of pharmaceutical products and provision of TCM-related services.
- Derives income from property leasing activities.
Contexto de la Industria
China Traditional Chinese Medicine Holdings Co. Limited operates within the growing Chinese pharmaceutical market, specifically focusing on traditional Chinese medicine. The TCM market is driven by increasing consumer awareness of natural remedies and government support for the industry. However, the industry faces challenges such as stringent regulations, quality control issues, and competition from both domestic and international players. The company's established presence and integrated operations provide a competitive advantage, but it must navigate these challenges to maintain its market position.
Clientes Clave
- Hospitals throughout China.
- Retail pharmacies across China.
- Patients seeking TCM treatments.
- Other pharmaceutical companies (through trading activities).
Finanzas
Gráfico e información
Precio de la acción de China Traditional Chinese Medicine Holdings Co. Limited (CHIZF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para CHIZF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CHIZF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para CHIZF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de CHIZF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Jun Yang
Unknown
Information on Jun Yang's background is not available in the provided data. Details regarding his career history, education, and previous roles are unknown. Further research would be needed to provide a comprehensive profile.
Historial: Information on Jun Yang's track record is not available in the provided data. Specific achievements, strategic decisions, and company milestones under his leadership are unknown. Further research would be needed to provide a detailed assessment.
Información del mercado OTC de CHIZF
The OTC Other tier represents the lowest tier of the OTC market, indicating that China Traditional Chinese Medicine Holdings Co. Limited may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB, or major exchanges like NYSE or NASDAQ. Companies in this tier often have limited operating history, are thinly traded, and may not be subject to stringent regulatory oversight. This contrasts with listed exchanges, which have specific listing standards and reporting requirements designed to protect investors.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited Disclosure: OTC companies often have less stringent disclosure requirements, making it difficult to assess their financial health and operational performance.
- Low Liquidity: OTC stocks can be thinly traded, leading to wide bid-ask spreads and difficulty in buying or selling shares.
- Regulatory Oversight: OTC markets are subject to less regulatory oversight than major exchanges, increasing the risk of fraud and manipulation.
- Price Volatility: OTC stocks can be more volatile than those listed on major exchanges due to lower trading volumes and less institutional interest.
- Information Asymmetry: Limited access to information can create an uneven playing field for investors.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and corporate governance.
- Check for any legal or regulatory issues.
- Monitor trading activity and liquidity.
- Consult with a financial advisor.
- Long operating history (founded in 1573).
- Presence in the Chinese market.
- Number of employees (16753).
- Tangible business operations (research, development, production, and sale of TCM products).
- Involvement in the cultivation of Chinese medicinal herbs.
Preguntas Comunes Sobre CHIZF
¿Cuáles son los factores clave para evaluar CHIZF?
China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) actualmente tiene una puntuación IA de 44/100, indicando puntuación baja. Fortaleza clave: Long-standing history and established brand in the TCM market.. Riesgo principal a monitorear: Potential: Stringent regulations and quality control requirements in the pharmaceutical industry.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de CHIZF?
CHIZF actualmente puntúa 44/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de CHIZF?
Los precios de CHIZF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre CHIZF?
La cobertura de analistas para CHIZF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en CHIZF?
Las categorías de riesgo para CHIZF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Stringent regulations and quality control requirements in the pharmaceutical industry.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de CHIZF?
La relación P/E para CHIZF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está CHIZF sobrevalorada o infravalorada?
Determinar si China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de CHIZF?
China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights in the future.
- OTC market data may be limited and less reliable than data for listed exchanges.